Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)

Trimodal therapy (TMT) consisting of transurethral resection of bladder tumors followed by radiotherapy and chemotherapy is a therapeutic alternative in patients with Muscle-Infiltrating Bladder Cancer who are inoperable or refuse surgery. One of the main challenges of TMT is the planning and delivery of radiation therapy. Indeed, the bladder is a mobile hollow organ subject to repletion, with variations in size and shape during and between radiotherapy sessions. Standard radiotherapy techniques require large planning target volume margins around the bladder, which can be responsible for irrad

Trial Details

NCT ID
NCT07043543
Phase
NA
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • Adaptive radiotherapy
  • standard radiotherapy
Locations (sample)
  • Dijon, Côte D'or, France|47.31344,5.01391
  • Montpellier, Herault, France|43.61093,3.87635
  • Rennes, Ille Et Vilaine, France|48.11109,-1.67431
  • Saint-Herblain, Loire Atlantique, France|47.21154,-1.651
  • Lille, Nord, France|50.63391,3.05512

Key Eligibility Criteria

  • Histologically proven muscle-infiltrating bladder cancer (de novo MIBC or after a history of non-muscle-invasive bladder cancer) or patients with i…
  • Age ≥ 18 years;
  • Urothelial carcinoma (transitional cell carcinoma of the bladder, micropapillary, microcystic with trophoblastic differenciation) and squamous cell…
  • Stage T1-T4aN0M0

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →